Remnant of a tumor or cancer after primary, potentially curative therapy.
| Excerpt | Reference |
|---|
| "To detect the minimal residual disease (MRD) in acute promyelocytic leukaemia patients treated with all-trans retinoic acid, we compared the sensitivity of metaphase fluorescence in situ hybridization (FISH) with conventional analysis of G-banded metaphases." | ( Emilia, G; Ferrari, MG; Gandini, G; Giacobbi, F; Temperani, P; Vaccari, P, 1995) |
| "We report the results of assessment of minimal residual disease in four patients with chronic lymphocytic leukaemia, who achieved clinical and haematological complete response following treatment with fludarabine." | ( Hopkins, JA; Howe, D; Johnson, SA; Phillips, MJ; Richardson, DS, 1994) |
| "A belief that minimal residual disease has a high probability of being cured with adjuvant therapy prompted Japanese investigators to develop the D2 dissection with extended lymphadenectomy, more detailed pathologic staging, perioperative chemotherapy, and chemoimmunotherapy." | ( Fukushima, M, 1996) |
| "Patients with residual tumor on posttreatment biopsy were treated with a salvage regimen that consisted of additional pelvic RT (9 Gy), 5-FU, and cisplatin (100 mg/m2)." | ( Coia, L; Doggett, S; Flam, M; John, M; Kerman, H; Murray, K; Myerson, R; Pajak, TF; Petrelli, N; Quivey, J; Rotman, M, 1996) |
| "This study examines detection of minimal residual disease by immunohistological staining using the monoclonal antibody (MoAb) B-ly 7 in 11 patients with complete remission of hairy cell leukemia (HCL) after 2-CdA therapy administered between 1990 and 1993." | ( Fend, F; Geisen, F; Hilbe, W; Knoblechner, A; Konwalinka, G; Petzer, A; Schirmer, M; Thaler, J, 1995) |
| "We investigated how residual tumour burden after cytoreductive surgery was related to the occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first chemotherapy course." | ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1996) |
| "Chemotherapy is reserved to treat minimal residual disease postoperatively." | ( De Kraker, J; Hoefnagel, CA; Valdés Olmos, RA; Voûte, PA, 1995) |
| "Minimal residual tumor or minimal residual metastatic disease is a major clinical problem for detection and treatment." | ( Emi, Y; Holden, SA; Kakeji, Y; Northey, D; Teicher, BA, 1997) |
| "Resection of residual tumors after first-line chemotherapy remains essential in the treatment of metastatic testicular cancer." | ( Bokemeyer, C; Candelaria, M; Hartmann, JT; Kuczyk, MA; Schmoll, HJ, 1997) |
| "We also attempted to study residual tumors after chemotherapy to determine if the p53 status of the tumor changed." | ( Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Kim, HJ; Lowe, V; McDonough, EM; Minster, J; Rodriguez, J; Varvares, MA, 1997) |
| "Contrast-enhanced US may depict residual tumor after RF application and thereby enable additional directed therapy." | ( Dellanoce, M; Gazelle, GS; Goldberg, SN; Ierace, T; Livraghi, T; Solbiati, L, 1999) |
| "It is also useful in differentiating residual tumor or tumor recurrence from posttherapy changes in patients with head and neck tumors." | ( Koh, JH; Pai, M; Park, CH; Suh, JH, 1999) |
| "Aiming to target the minimal residual disease in patients with multiple myeloma, a phase I/II single centre study was undertaken for feasibility and tolerance of intensive acute lymphoblastic leukaemia consolidation chemotherapy (ALL-IC) as part of a strategy for post-transplant consolidation targeted at pre-B cells." | ( Bhagwati, N; Horton, C; Kulkarni, S; Mehta, J; Powles, R; Raje, N; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2000) |
| "The detection of minimal residual disease (MRD) using immunoglobulin and T-cell receptor (TCR) rearrangements as PCR targets provides important prognostic information on the in vivo effectiveness of treatment in acute lymphoblastic leukemia (ALL)." | ( Bartram, CR; Flohr, T; Janssen, JW; Nakao, M, 2000) |
| "Tumor regression rate, residual tumor grade, and histologic regression grade to the preoperative therapy were analyzed to determine their influence on the prognosis." | ( Kirita, T; Nishimine, M; Shimooka, H; Sugimura, M; Tatebayashi, S; Yamamoto, K; Yamanaka, Y, 2001) |
| "To measure residual tumour in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy, to correlate specific pathological variables with survival, and to describe morphological changes in tumour and non-neoplastic tissue resulting from preoperative treatment." | ( Dunne, B; Griffin, M; Kelly, A; Mulligan, E; Reynolds, JV, 2001) |
| "In this respect, minimal residual disease status during this phase of treatment may prove to be a useful pharmacodynamic endpoint." | ( Estlin, EJ, 2001) |
| "Nine of ten patients had PCR-detectable residual tumor cells in the peripheral blood after therapy." | ( Barth, S; Borchmann, P; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Reiser, M; Schinköthe, T; Schulz, H; Tur, M; Wessels, J, 2002) |
| "In this series confined to patients with minimal residual disease after initial therapy subjected to second-line intraperitoneal treatment, it appears to identify a poor prognostic (positive) subset for survival." | ( Alberts, DS; Belt, RJ; Cote, R; Felix, J; Hawes, D; Liu, PY; Muggia, FM; Terada, K; Wilczynski, S, 2002) |
| "Bone-marrow minimal residual disease (MRD) causes relapse after chemotherapy in patients with acute myelogenous leukemia (AML)." | ( Akiyama, T; Fujimi, A; Hirayama, Y; Kato, J; Kawano, Y; Kobune, M; Kohda, K; Kuroda, H; Matsunaga, T; Miyake, K; Niitsu, Y; Sakamaki, S; Sato, T; Takemoto, N; Takimoto, R; Tanaka, I, 2003) |
| "Clinical response and residual tumor size were evaluated in 108 treated patients who completed a clinical trial with paclitaxel and then received combined 5-fluorouracil, doxorubicin, and cyclophosphamide chemotherapy." | ( Buzdar, AU; Fiterman, DJ; Frye, D; Gal-Gombos, E; Green, M; Hortobagyi, GN; Kuerer, H; Poniecka, A; Pusztai, L; Rajan, R; Rouzier, R; Smith, TL; Symmans, WF; Whitman, G; Yang, Y, 2004) |
| "To assess the role of residual tumor resection performed after high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ cell tumors (GCT)." | ( Beyer, J; Bokemeyer, C; Braun, T; Hartmann, JT; Hartmann, M; Pottek, T; Rachud, B; Rick, O; Schirren, J; Siegert, W; Weinknecht, S; Weissbach, L, 2004) |
| "By analyzing minimal residual disease (MRD) under the levels of CCR, we tried to assess the molecular response after imatinib therapy." | ( Goh, HG; Kim, CC; Kim, DW; Kim, HJ; Kim, SH; Kim, TG; Kim, YJ; Kim, YL; Lee, JW; Lee, JY; Lee, S; Min, CK; Min, WS, 2004) |
| "Complete response (no residual tumour, TRG 1) was seen in 7% of the patients (3/44) and total or major regression (TRG 1-3) in 73% of the patients (32/44) treated with 50-Gy chemoradiation." | ( Jantunen, I; Juhola, M; Kairaluoma, M; Kellokumpu, I; Vironen, J, 2005) |
| "For patients who have significant residual tumor after resection or relapse after radiation, the proper chemotherapy regimen has not yet been identified." | ( Ahn, SD; Ghim, TT; Goo, HW; Khang, SK; Kim, YJ; Lee, MJ; Park, JB; Ra, YS; Song, JS, 2006) |
| "Of the 13 children with a residual tumour, chemotherapy induced 2 partial responses (PR), 1 minor response (MR) and 1 stable disease (SD) with no recurrent disease." | ( Chastagner, P; Doz, F; Dufour, C; Frappaz, D; Gentet, JC; Grill, J; Kalifa, C; Lellouch-Tubiana, A; Pichon, F; Plantaz, D; Puget, S; Raquin, MA, 2006) |
| "The concept of minimal residual disease (MRD) eradication in chronic lymphocytic leukaemia (CLL) is a relatively new one, as conventional therapy with alkylating agents is relatively ineffective and responding patients almost always have a significant tumour burden remaining at the end of treatment." | ( Hillmen, P; Rawstron, AC; Sayala, HA, 2007) |
| "Therefore, monitoring of minimal residual disease (MRD) during treatment with imatinib is important." | ( Agis, H; Esterbauer, H; Geissler, K; Haas, OA; Herndlhofer, S; Jäger, U; Mannhalter, C; Pirc-Danoewinata, H; Semper, H; Sillaber, C; Sperr, WR; Valent, P, 2007) |
| "The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) treated with imatinib-combined chemotherapy." | ( Akiyama, H; Jinnai, I; Kimura, Y; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Narimatsu, H; Nishii, K; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M; Yujiri, T, 2008) |
| "Prospective assessment of the extent of minimal residual disease reduction after the first 4-week imatinib therapy may allow the authors to identify subgroups of Ph-positive ALL transplants at high risk of relapse." | ( Chung, NG; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Lim, J; Min, CK; Min, WS, 2009) |
| "Molecular monitoring of minimal residual disease levels appears to have prognostic relevance and should be used to guide treatment." | ( Ottmann, OG; Pfeifer, H, 2009) |
| "A pathologic complete response (pCR) and minimal residual disease (pMRD) after preoperative chemotherapy (PCT) for early stage or locally advanced breast cancer (BC) correlates with a good prognosis." | ( Bernardi, A; Cacciari, N; Fanti, S; Martoni, AA; Musto, A; Quercia, S; Rosati, M; Santini, D; Taffurelli, M; Zamagni, C, 2010) |
| "The sensitive detection of minimal residual disease by the polymerase chain reaction (PCR) has revolutionized our ability to follow treatment response and predict relapse." | ( Oehler, VG; Radich, JP, 2006) |
| "Radiotherapy was planned for residual tumor after the completion of chemotherapy or for progression." | ( Balter, R; Barra, S; Bertin, D; Biassoni, V; Cama, A; Casali, C; Collini, P; Di Rocco, C; Fidani, P; Gandola, L; Garrè, ML; Genitori, L; Giangaspero, F; Mascarin, M; Massimino, M; Milanaccio, C; Milano, GM; Modena, P; Nozza, P; Peretta, P; Potepan, P; Sardi, I; Scarzello, G; Tamburrini, G; Viscardi, E, 2011) |
| "The median duration of negative minimal residual disease (MRD) in patients with post-transplant imatinib administration was 6 months in the pre-emptive administration group, where imatinib was administered upon detecting MRD after allogeneic stem cell transplantation (allo-SCT)." | ( Harigae, H; Kato, C; Kodera, Y; Miyamura, K; Nakao, S; Nishiwaki, S; Ohashi, K; Sakamaki, H; Terakura, S, 2010) |
| "The presence and volume of residual tumor in LABC patients treated with NAC can be accurately evaluated by DMRI." | ( Gu, YJ; Mao, J; Peng, WJ; Tan, HN; Tang, F; Wang, XH; Xin, C, 2010) |
| "Patients with residual tumors after the initial treatment had a response rate of 47." | ( Katsuno, M; Sato, N; Sugio, Y; Tachibana, S; Tani, Y; Watanabe, N; Zusho, H, 2010) |
| "In addition, minimal residual disease (MRD) in the marrow was studied 2 months after therapy, with MRD negativity defined as <0·01% CLL cells." | ( Booth, GA; Brown, J; Cocks, K; Cohen, DR; Dearden, C; Ezekwisili, R; Fegan, C; Hillmen, P; Kennedy, DB; Mercieca, J; Milligan, DW; Pettitt, A; Pocock, C; Radford, J; Rawstron, AC; Sayala, HA; Smith, AF; Varghese, AM, 2011) |
| "Categoric assessments of residual tumor by PET/CT and physical examination 4-6 months after therapy were correlated and compared with clinical outcomes." | ( Blumin, J; Campbell, BH; Maheshwari, M; Massey, BL; Michel, MA; Schultz, CJ; Wang, D; Wilson, JF; Wong, SJ; Zundel, MT, 2011) |
| "Furthermore, serpinB3 status in residual tumour is a biomarker of neoadjuvant docetaxel benefit in patients not achieving a pCR and use of serpinB3 molecular subtyping for adjuvant docetaxel treatment planning warrants further investigation." | ( Collie-Duguid, ES; Heys, SD; Miller, ID; Smyth, E; Stewart, KN; Sweeney, K, 2012) |
| "This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34(+) blood cells to pre-empt relapse in patients with CD34(+) myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT)." | ( Bornhäuser, M; Ehninger, G; Graehlert, X; Kiani, A; Klut, IM; Knoth, H; Mohr, B; Oelschlaegel, U; Platzbecker, U; Radke, J; Röllig, C; Schetelig, J; Seltmann, F; Thiede, C; Wermke, M, 2012) |
| "In the multivariate analysis, the residual tumor after the salvage surgery was the only significant variable associated with primary treatment failure (P = 0." | ( Hur, SY; Ki, EY; Lee, CW; Lee, KH; Lee, SJ; Park, JS; Park, ST; Ryu, KS; Song, MJ, 2011) |
| "Data on minimal residual disease (MRD) monitoring in acute promyelocytic leukemia (APL) are available only in the context of conventional all-trans retinoic acid plus chemotherapy regimens." | ( Abraham, A; Ahmed, R; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Ganesan, S; George, B; Janet, NB; Lakshmi, KM; Mathews, V; Nair, SC; Sitaram, U; Srivastava, A; Srivastava, VM; Viswabandya, A, 2012) |
| "These results demonstrate that minimal residual disease of Ph(+) ALL can be significantly better controlled by a combined treatment approach of immunotherapy and chemotherapy." | ( Arndt, S; Henze, G; Kalies, K; Köchling, J; Marschke, C; Rott, Y; Schmidt, M; Westermann, J; Wittig, B, 2012) |
| "Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery." | ( Bianchi, R; Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2013) |
| "The detection of minimal residual disease (MRD) via molecular genetic methods provides - in comparison with conventional clinical and biological parameters - much more sensitive approaches to monitor individual treatment response." | ( Bartram, CR; Koehler, R, 2013) |
| "To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research Council) Myeloma IX trial." | ( Bell, SE; Child, JA; Cook, G; Davies, FE; de Tute, RM; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Rawstron, AC; Ross, FM; Szubert, AJ, 2013) |
| "Preemptive AZA treatment for minimal residual disease has an acceptable safety profile and appears to be an effective strategy for preventing or substantially delaying hematological relapse in pediatric patients with high-risk myelodysplastic syndrome after HSCT." | ( Inoue, A; Kawakami, C; Takitani, K; Tamai, H, 2014) |
| "Patients with residual tumors >3 cm should undergo 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) computed tomography scanning after a minimum interval of 6 weeks after chemotherapy." | ( Krege, S; Müller, J; Schrader, M; Zengerling, F, 2014) |
| "Maintenance treatment also reduced minimal residual disease (detected by WT1 and CBFβ-MYH11) in five of eight evaluable patients." | ( Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L, 2014) |
| "Refining the role of minimal residual disease in directing treatment decisions is important." | ( Gore, SD; Zeidan, AM, 2014) |
| "Monitoring minimal residual disease (MRD) by using real-time quantitative polymerase chain reaction (RQ-PCR) provides information for patient stratification and individual risk-directed treatment." | ( Aricò, M; Barisone, E; Basso, G; Cazzaniga, G; Conter, V; Fabbri, G; Fagioli, F; Giraldi, E; Paganin, M; Polato, K; Valsecchi, MG, 2014) |
| "Nine days after CAF treatment, residual tumors showed features of regressive alterations and were composed of mesenchymal-like tumor cells, infiltrating immune cells and some tumor-associated fibroblasts with an intense deposition of collagen." | ( Alves, F; Deppert, W; Jannasch, K; Lenfert, E; Maenz, C; Wegwitz, F, 2015) |
| "Additional measurements of minimal residual disease were made on weeks 17, 48, and 120 (end of treatment)." | ( Bhojwani, D; Bowman, WP; Campana, D; Cheng, C; Coustan-Smith, E; Downing, JR; Evans, WE; Gruber, TA; Inaba, H; Jeha, S; Leung, WH; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT, 2015) |
| "Of patients attaining negative minimal residual disease status after remission induction, minimal residual disease re-emerged in four of 382 studied on week 7, one of 448 at week 17, and one of 437 at week 48; all but one of these six patients died despite additional treatment." | ( Bhojwani, D; Bowman, WP; Campana, D; Cheng, C; Coustan-Smith, E; Downing, JR; Evans, WE; Gruber, TA; Inaba, H; Jeha, S; Leung, WH; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT, 2015) |
| "RT-qPCR is used to quantify minimal residual disease (MRD) in chronic myeloid leukaemia (CML) in order to make decisions on treatment, but its results depend on the level of BCR-ABL1 expression as well as leukaemic cell number." | ( Bartley, PA; Branford, S; Budgen, B; Hughes, E; Hughes, TP; Latham, S; Morley, AA; Ross, DM; White, D, 2016) |
| "We assessed the minimal residual disease (MRD)-based effect and long-term outcome of first-line incorporation of dasatinib (100 mg once daily) into chemotherapy alternatively for adults with Ph-positive ALL." | ( Ahn, JS; Choi, CW; Choi, SY; Eom, HS; Kim, DW; Kim, JS; Kim, SH; Kim, SJ; Kwak, JY; Lee, JJ; Lee, S; Park, SJ; Park, SK; Yang, DH; Yhim, HY; Yoon, JH, 2016) |
| "With the growing importance of minimal residual disease (MRD) monitoring and the recent discover of IDH mutations in acute myeloid leukemia (AML), the quantification of this molecular marker provides the possibility to monitor the disease progression and the therapy efficacy." | ( Abdelhamid, E; Besbes, S; Helevaut, N; Nibourel, O; Preudhomme, C; Renneville, A; Soua, Z, 2016) |
| "Higher levels of minimal residual disease are associated with inferior results even with intensification of therapy, thus suggesting that identification and targeting of minimal residual disease cells could be a therapeutic strategy." | ( Bourquin, JP; Dempsey, C; Krishnan, S; McGinn, OJ; Saha, V; Sapra, P; Stern, PL, 2017) |
| "Evaluating Cyclin D1 overexpression in residual tumor could recognize those patients that benefit most from such post-neoadjuvant treatment." | ( Darb-Esfahani, S; Denkert, C; Engels, K; Furlanetto, J; Huober, J; Kümmel, S; Lederer, B; Loibl, S; Marmé, F; Mehta, K; Müller, V; Pfitzner, BM; Schem, C; Villegas, SL; von Minckwitz, G; Weber, K, 2018) |
| "Accurate quantification of minimal residual disease (MRD) during treatment of chronic myeloid leukemia (CML) guides clinical decisions." | ( Braley, J; Branford, S; Dang, P; Goyne, JM; Hughes, TP; Kommers, IO; Nicola, M; Pagani, IS; Ross, DM; Saunders, VA; White, DL; Yeung, DT, 2018) |
| "The pathologic complete response or minimal residual disease rate was 30% (n = 15 of 50) in ELAP-treated patients and 16% (n = four of 25) in EL-treated patients (two-sided P = ." | ( Bubley, GJ; Calagua, C; Chang, P; Chang, SL; Ellis, WJ; Harshman, LC; Kibel, AS; Lin, DW; Lis, R; McKay, RR; Montgomery, B; Pienta, KJ; Ross, AE; Taplin, ME; Trinh, QD; Wagner, AA; Xie, W; Ye, H; Zhang, Z, 2019) |
| "Importantly, residual tumors could be ablated through intraoperative photothermal therapy without obvious recurrence." | ( Hao, L; Huang, J; Song, J; Wang, D; Wang, Z; Yang, Z; Yi, H; Zhang, L; Zhang, N; Zhong, Y, 2019) |
| "After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%." | ( Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L, 2019) |
| "Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia." | ( Bijou, F; Durrieu, F; Filleron, T; Gauthier, M; Martin, E; Obéric, L; Peres, M; Quillet Mary, A; Vergez, F; Ysebaert, L, 2019) |
| "Finally, this article briefly reviews minimal residual disease directed therapy approaches, primarily in the context of whether eligible patients should be referred for high dose chemotherapy and autologous stem cell rescue." | ( Lu, SX, 2020) |
| "Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT)." | ( Bosch, LJW; Coupé, VMH; Elias, S; Fijneman, RJA; Koopman, M; Laclé, MM; Meijer, GA; Phallen, J; Rubio Alarcón, C; Sausen, M; Schraa, SJ; Simmons, J; van den Broek, D; van der Kruijssen, DEW; van Grevenstein, WMU; van Rooijen, KL; Velculescu, VE; Verkooijen, HM; Vink, GR, 2020) |
| "In our study cohort, MPO+ B-ALL showed minimal residual disease persistence less often after induction chemotherapy but otherwise had similar clinical outcomes to MPO- B-ALL, with similar rates of additional myeloid antigen aberrancy." | ( Au, N; Chipperfield, KM; Liu, L; McGinnis, E; Morrison, D; Setiadi, AF; Tsang, A; Vercauteren, SM; Yang, D, 2021) |
| "Achievement of minimal residual disease negativity was greatest in 1L patients treated with G-FC." | ( Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M, 2021) |
| "Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored." | ( Assouline, S; Boyer, M; Cartron, G; Chyla, B; D'Rozario, J; de la Serna, J; Eichhorst, BF; Jaeger, U; Jiang, Y; Kater, AP; Kipps, TJ; Lamanna, N; Lefebure, M; Lu, T; Mellink, C; Montillo, M; Owen, CJ; Panchal, A; Robak, T; Seymour, JF; Wu, JQ, 2022) |
| "Achieving minimal residual disease (MRD) negativity following treatment for multiple myeloma (MM) is associated with improved progression free and overall survival." | ( Ainley, L; Camilleri, M; Galas-Filipowicz, D; Guo, Y; Lecat, C; McMillan, A; Sive, J; Tran, TA; Yong, K, 2023) |
| "A centralized assessment of minimal residual disease (MRD) was performed by allele-specific oligonucleotide polymerase chain reaction assay on the peripheral blood and bone marrow at the end of treatment (EOT) and during the follow-up." | ( Albano, F; Arcari, A; Arena, V; Casaluci, GM; Coscia, M; Cuneo, A; De Novi, LA; De Propris, MS; Del Giudice, I; Deodato, M; Fazi, P; Foà, R; Galieni, P; Giordano, A; Gottardi, D; Guarini, A; Ilariucci, F; Laurenti, L; Levato, L; Liberati, AM; Mannina, D; Marasca, R; Marchetti, M; Massaia, M; Mattiello, V; Mauro, FR; Messina, M; Molinari, MC; Murru, R; Musuraca, G; Nanni, M; Neri, A; Orsucci, L; Patrizi, VB; Piciocchi, A; Pietrasanta, D; Reda, G; Rigolin, GM; Scarfò, L; Sportoletti, P; Starza, ID; Stelitano, C; Tani, M; Trentin, L; Vignetti, M; Visentin, A; Vitale, C, 2023) |
| "The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated for ibrutinib + venetoclax treatment." | ( Baeten, K; Benjamini, O; Caces, DB; Follows, G; Howes, A; Janssens, A; Kater, AP; Levin, MD; Moreno, C; Munir, T; Niemann, CU; Osterborg, A; Owen, C; Parisi, L; Qi, K; Qi, Q; Robak, T; Schuier, N; Simkovic, M; Srinivasan, S; Stevens, D; Voloshin, S; Vorobyev, V; Yagci, M; Ysebaert, L, 2023) |
| "The median residual tumor size following neoadjuvant chemotherapy was 12 mm (range; 1-60)." | ( Blohmer, JU; Böhmer, G; Domröse, C; Favero, G; Hertel, H; Jacob, A; Jülicher, A; Köhler, C; Marnitz, S; Oppelt, P; Petzel, A; Plaikner, A; Ragosch, V; Schneider, A; Schubert, M; Siegler, K; Willems, A, 2023) |
| "This accelerates the recurrence of residual tumors and causes resistance to anti-PD-1/PDL1 therapy, which bringing a great clinical challenge in residual tumors immunotherapy." | ( Chen, H; Huang, Y; Li, L; Lin, Y; Pi, S; Su, Z; Wu, C; Ye, F; Ye, Q; Zhang, S, 2023) |